よむ、つかう、まなぶ。
【参考資料5】抗微生物薬適正使用の手引き 第三版 別冊 (38 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
別冊
30. Rodriguez-Bano J, Picon E, Gijon P. et al. Community-onset bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect
Dis. 2010 Jan;50(1):40-48.
31. Goodman KE, Lessler J, Cosgrove SE. et al. A Clinical Decision Tree to Predict Whether a
Bacteremic Patient Is Infected With an Extended-Spectrum beta-Lactamase-Producing
Organism. Clin Infect Dis. 2016 Oct;63(7):896-903.
32. CSLI M100-32nd Edition. at http://em100.edaptivedocs.net/dashboard.aspx,.)
33. 一般社団法人日本臨床微生物学会 多剤耐性菌検査の手引き. 2021. at
https://www.jscm.org/modules/guideline/index.php?content_id=15.)
34. Nicolle LE, Gupta K, Bradley SF. et al. Clinical Practice Guideline for the Management of
Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin
Infect Dis. 2019 May;68(10):e83-e110.
35. Armand-Lefevre L, Angebault C, Barbier F. et al. Emergence of imipenem-resistant gramnegative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother.
2013 Mar;57(3):1488-1495.
36. Ishikawa K, Uehara Y, Mori N. et al. In Vitro Activity and Clinical Efficacy of Faropenem
against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella
pneumoniae. Antimicrob Agents Chemother. 2022 Jun;66(6):e0012522.
37. Eckburg PB, Muir L, Critchley IA. et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated
Urinary Tract Infection. N Engl J Med. 2022 Apr;386(14):1327-1338.
38. Hamada Y, Kasai H, Suzuki-Ito M, Matsumura Y, Doi Y, Hayakawa K.
Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and
Flomoxef against Extended-Spectrum beta-Lactamase-Producing Enterobacterales in
Patients with Invasive Urinary Tract Infection Considering Renal Function. Antibiotics (Basel).
2022 Mar;11(4):456.
39. Hayakawa K, Matsumura Y, Uemura K. et al. Effectiveness of cefmetazole versus
meropenem for invasive urinary tract infections caused by extended-spectrum betalactamase-producing Escherichia coli. Antimicrob Agents Chemother 2023
Oct;67(10):e0051023.
40. JAID/JSC 感染症治療ガイド・ガイドライン作成委員会 JAID/JSC 感染症治療ガイド 2019.
ライフサイエンス出版;2019
41. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases
Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant GramNegative Infections. Clin Infect Dis. 2023 Jul:ciad428.
42. Rodriguez-Bano J, Alcala JC, Cisneros JM. et al. Community infections caused by extendedspectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008
Sep;168(17):1897-1902.
43. Lo CL, Lee CC, Li CW. et al. Fluoroquinolone therapy for bloodstream infections caused by
extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J
Microbiol Immunol Infect. 2017 Jun;50(3):355-61.
38
第三版
別冊
30. Rodriguez-Bano J, Picon E, Gijon P. et al. Community-onset bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect
Dis. 2010 Jan;50(1):40-48.
31. Goodman KE, Lessler J, Cosgrove SE. et al. A Clinical Decision Tree to Predict Whether a
Bacteremic Patient Is Infected With an Extended-Spectrum beta-Lactamase-Producing
Organism. Clin Infect Dis. 2016 Oct;63(7):896-903.
32. CSLI M100-32nd Edition. at http://em100.edaptivedocs.net/dashboard.aspx,.)
33. 一般社団法人日本臨床微生物学会 多剤耐性菌検査の手引き. 2021. at
https://www.jscm.org/modules/guideline/index.php?content_id=15.)
34. Nicolle LE, Gupta K, Bradley SF. et al. Clinical Practice Guideline for the Management of
Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin
Infect Dis. 2019 May;68(10):e83-e110.
35. Armand-Lefevre L, Angebault C, Barbier F. et al. Emergence of imipenem-resistant gramnegative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother.
2013 Mar;57(3):1488-1495.
36. Ishikawa K, Uehara Y, Mori N. et al. In Vitro Activity and Clinical Efficacy of Faropenem
against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella
pneumoniae. Antimicrob Agents Chemother. 2022 Jun;66(6):e0012522.
37. Eckburg PB, Muir L, Critchley IA. et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated
Urinary Tract Infection. N Engl J Med. 2022 Apr;386(14):1327-1338.
38. Hamada Y, Kasai H, Suzuki-Ito M, Matsumura Y, Doi Y, Hayakawa K.
Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and
Flomoxef against Extended-Spectrum beta-Lactamase-Producing Enterobacterales in
Patients with Invasive Urinary Tract Infection Considering Renal Function. Antibiotics (Basel).
2022 Mar;11(4):456.
39. Hayakawa K, Matsumura Y, Uemura K. et al. Effectiveness of cefmetazole versus
meropenem for invasive urinary tract infections caused by extended-spectrum betalactamase-producing Escherichia coli. Antimicrob Agents Chemother 2023
Oct;67(10):e0051023.
40. JAID/JSC 感染症治療ガイド・ガイドライン作成委員会 JAID/JSC 感染症治療ガイド 2019.
ライフサイエンス出版;2019
41. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases
Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant GramNegative Infections. Clin Infect Dis. 2023 Jul:ciad428.
42. Rodriguez-Bano J, Alcala JC, Cisneros JM. et al. Community infections caused by extendedspectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008
Sep;168(17):1897-1902.
43. Lo CL, Lee CC, Li CW. et al. Fluoroquinolone therapy for bloodstream infections caused by
extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J
Microbiol Immunol Infect. 2017 Jun;50(3):355-61.
38